Diagnostik und Psychopharmakotherapie depressiver Erkrankungen bei Herz-Kreislauf-Patienten vor konsiliarpsychiatrischem Hintergrund
Tóm tắt
Từ khóa
Tài liệu tham khảo
Azaz-Livshits TL, Danenberg HD (1997) Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopsychiatry 30:274–275
Beliles K, Stoudemire A (1998) Psychopharmacologic treatment of depression in the medically ill. Psychosomatics 39:2–19
Bottlender R, Dobmeier P, Möller HJ (1998) Der Einfluß von selektiven Serotonin-Wiederaufnahmeinhibitoren auf die Blutgerinnung. Fortschr Neurol Psychiat 66:32–35
Combes A, Peytavin G, Theron D (2001) Conduction disturbances associated with venlafaxine. Ann Intern Med 134:166–167
Cozza KL, Armstrong SC (2001) The Cytochrome P450 system. Drug interaction principles for medical practice. Am Psychiatric Press, Washington, pp 121–129
DeVane CL, Markowitz JS (2000) Avoiding psychotropic drug interactions in the cardiovascular patient. Bull Menninger Clin 64:49–59
Duncan D, Sayal K, McConnell H, Taylor D (1998) Antidepressant interactions with warfarin. Int Clin Psychopharmacol 13:87–94
Feighner JP (1995) Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 56:574–579
Gastpar M, Singer A, Zeller K (2006) Comparative efficacy and safety of a once daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a doubleblind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 39:66–75
Glassman AH, O'Connor CM, Califf RM et al. (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288:701–709
Gröchenig HP (2001) Interaktionspotential der Statine. J Kardiol 8:306–311
Holtzman JL, Weeks CE, Kvam DC et al. (1989) Identification of drug interactions by meta-analysis of premarketing trials. The effect of smoking on the pharmacokinetic and dosage requirements for flecainide acetate. Clin Pharmacol Ther 46:1–8
James SP, Mendelson WB (2004) The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry 65:752–755
Karhova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE (2000) Interaction of Hypericum perforatum (St. John's wort) with ciclosporin A metabolism in a patient after liver transplantation. J Hepatol 33:853–855
Katona C, Bercoff E, Chiu E, Tack P, Versiani M, Woelk H (1999) Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J Affect Disord 55:203–213
Khawaja IS, Feinstein RE (2003) Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants. Heart Dis 5:153–160
Kirchheiner J, Ufer M, Walter EC et al. (2004) Effects of CYP2C9 polymorphisms on the pharmacokinetics of Rand S-phenprocoumon in healthy volunteers. Pharmacogenetics 14:19–26
Liu BA, Mittmann N, Knowles SR, Shear NH (1996) Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ 155:519–527
Nashoni E, Weitzmann A, Shefet D, Pik N (2004) A case of hyponatremia associated with escitalopram. J Clin Psychiatry 65:1722
Preskorn SH, Greenblatt DJ, Flockhart D et al. (2007) Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 27:28–34
Regina W, Vandel P, Vandel S, Sechter D, Bizouard P (1999) Clinical tolerance of a new antidepressant – milnacipran. Encephale 25:252–258
Röder C, Schaefer M, Leucht S (2004) Meta-Analyse zu Wirksamkeit und Verträglichkeit der Behandlung der leichten und mittelschweren Depression mit Johanniskraut. Fortschr Neurol Psychiat 72:330–343
Roose SP, Laghrissi-Thode F, Kennedy JS et al. (1998) Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279:287–291
Rothenhäusler HB, Haberl C, Ehrentraut S, Kapfhammer HP, Weber MM (2000) Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker. Pharmacopsychiatry 33:150–152
Rothenhäusler HB, Kapfhammer HP (2005) Psychopharmakotherapie bei somatischen Erkrankungen – Behandlungsprinzipien in der medizinischen Routineversorgung. Wien Med Wochenschr 155:303–314
Sayal KS, Duncan-McConnell DA, McConnell HW, Taylor DM (2000) Psychotropic interactions with warfarin. Acta Psychiatr Scand 102:250–255
Strain JJ, Caliendo G, Alexis JD, Lowe RS 3rd, Karim A, Loigman M (1999) Cardiac drug and psychotropic drug interactions: significance and recommendations. Gen Hosp Psychiatry 21:408–429
Strik JJ, Honig A, Lousberg R et al. (2000) Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 62:783–789
van den Brink RH, van Melle JP, Honig A, Schene AH, Crijns HJ, Lambert FP, Ormel J (2002) Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial Infarction and Depression- Intervention Trial (MIND-IT). Am Heart J 144:219–225
Zellweger MJ, Osterwalder RH, Langewitz W, Pfisterer ME (2004) Coronary artery disease and depression. Eur Heart J 25:3–9
Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304